Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

Inclusion criteria : * Histologically confirmed, unresectable locally advanced squamous cell carcinoma of head and neck of oral cavity in stage III-IV without evidence of distant metastases. * No prior chemotherapy or radiation therapy. * Having at least one measurable lesion in one dimension. * Age ≥18 and \<65 years with Eastern Cooperative Oncology Group ≤ 1. * Adequate organ function: * Adequate hematological function * Adequate hepatic function * Renal function within normal limits Exclusion criteria: * Peripheral neuropathy \> grade 1 or other serious diseases (unstable ischaemic heart disease, acute myocardial infarction six months prior to inclusion, history of significant neurological or psychiatric disorder or active peptic ulcer). * Being treated concomitantly with corticosteroids (except as pre-medication). * Patients having another type of cancer. * Previous chemotherapy or radiotherapy. * Any previous definitive surgery for squamous cell carcinoma of head and neck. * Severe weight loss (\> 20 % of body weight) in the preceding 3 months. * Hearing loss (\> grade 2). * Pregnancy (pregnancy test result for women of childbearing potential). * Sexually active females with lack of adequate contraception. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.